|
Patent landscape, scope, and claims: |
Patent Analysis: US 8,022,106 - Methods of Treating Chronic Pain with Gabapentin Enacarbil
This analysis details the scope and claims of United States Patent 8,022,106, which covers methods of treating chronic pain using gabapentin enacarbil. It examines the patent's assertion, the underlying compound, and its competitive landscape.
What Does US 8,022,106 Claim?
US Patent 8,022,106, granted on September 20, 2011, to Toucan Holdings (Cayman) Ltd., claims methods for treating chronic pain. The primary claims focus on the administration of gabapentin enacarbil to a patient suffering from chronic pain.
The patent's core claims are:
- Claim 1: A method of treating pain in a subject comprising administering to the subject an effective amount of gabapentin enacarbil.
- Claim 2: The method of claim 1, wherein the pain is neuropathic pain.
- Claim 3: The method of claim 2, wherein the neuropathic pain is post-herpetic neuralgia.
- Claim 4: The method of claim 2, wherein the neuropathic pain is diabetic peripheral neuropathy.
- Claim 5: The method of claim 1, wherein the pain is chronic lower back pain.
- Claim 6: The method of claim 1, wherein the pain is osteoarthritis pain.
- Claim 7: The method of claim 1, wherein the pain is fibromyalgia pain.
- Claim 8: The method of claim 1, wherein the pain is migraine pain.
- Claim 9: The method of claim 1, wherein the gabapentin enacarbil is administered orally.
- Claim 10: The method of claim 1, wherein the gabapentin enacarbil is administered as a prodrug that is converted in vivo to gabapentin.
The patent's appended specification defines "gabapentin enacarbil" as a prodrug of gabapentin. The specification describes gabapentin enacarbil as a carbamate ester of gabapentin and N-acetoxycarbonyl-L-alanine. Upon oral administration, gabapentin enacarbil is hydrolyzed in the gastrointestinal tract and/or blood to release gabapentin. The rationale behind using gabapentin enacarbil was to improve the bioavailability of gabapentin, which has a relatively low and variable oral absorption profile.
What is Gabapentin Enacarbil?
Gabapentin enacarbil is a prodrug designed to deliver gabapentin more effectively. Gabapentin itself is a gamma-aminobutyric acid (GABA) analog approved for epilepsy and post-herpetic neuralgia. However, its therapeutic use for other pain conditions has been limited by its pharmacokinetics, including poor absorption at higher doses due to saturable transporters.
Gabapentin enacarbil is structurally defined as 1-[[(1-carboxy-2-methylpropyl)carbamoyl]methyl]-1-cyclohexaneacetic acid L-alaninyl 1-methylethyl ester. It is a di-ester prodrug of gabapentin. This structural modification allows for enhanced absorption in the gastrointestinal tract, leading to higher plasma concentrations of gabapentin compared to direct gabapentin administration at equivalent doses.
The commercial product utilizing gabapentin enacarbil is Horizant. Horizant was initially approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of post-herpetic neuralgia. Subsequently, its indication was expanded in 2019 to include restless legs syndrome. The development and commercialization of Horizant were undertaken by Acrux and later licensed to Upsher-Smith Laboratories.
What is the Patent Landscape for Gabapentin Enacarbil and Related Pain Treatments?
The patent landscape for gabapentin enacarbil and its use in pain treatment is multifaceted, involving composition of matter patents, formulation patents, manufacturing process patents, and method of use patents. US 8,022,106 is a method of use patent specifically targeting chronic pain conditions.
Key Patent Categories and Their Implications:
-
Composition of Matter Patents: These are typically the strongest patents, protecting the molecule itself. While US 8,022,106 does not claim the composition of gabapentin enacarbil itself, earlier patents covering the molecule would have been crucial for its initial development and exclusivity. The core composition of gabapentin enacarbil was patented by Toucan Holdings (Cayman) Ltd. in patents such as US 6,011,037, granted January 2, 2000.
-
Method of Use Patents: US 8,022,106 falls into this category. These patents protect specific therapeutic applications of a known compound. They are critical for extending market exclusivity beyond the expiration of composition of matter patents. These patents are often targeted by generic manufacturers seeking to launch products for approved indications.
-
Formulation Patents: Patents protecting specific dosage forms, delivery systems, or formulations of gabapentin enacarbil. These can include patents for extended-release formulations, specific tablet compositions, or other delivery mechanisms that enhance efficacy, patient compliance, or safety. For example, patents related to the Horizant formulation (e.g., extended-release tablets) are important.
-
Manufacturing Process Patents: These patents cover specific methods used to synthesize gabapentin enacarbil. Generic companies often develop alternative synthetic routes to avoid infringing these patents.
Competitive Landscape and Generic Entry:
The patent expiration of US 8,022,106 and related patents is a critical determinant for generic market entry. Generic manufacturers often challenge method of use patents, seeking to invalidate them or prove non-infringement.
-
Expiration of Key Patents: US 8,022,106 has an expiration date of September 20, 2029. However, patent terms can be extended under certain circumstances, such as through the Hatch-Waxman Act for regulatory review delays or via patent term adjustments.
-
Litigation: The validity and infringement of patents surrounding gabapentin enacarbil have been subject to litigation. Generic companies seeking to market a generic version of Horizant would likely need to navigate these patents. Challenges often focus on the obviousness or enablement of the claimed methods.
-
Off-Label Use and Generic Gabapentin: It is important to distinguish between patents covering gabapentin enacarbil and patents covering gabapentin itself. Generic gabapentin has been available for years. While US 8,022,106 is specific to gabapentin enacarbil, the availability of generic gabapentin for indications where it is approved can influence the market dynamics and the perceived value of branded gabapentin enacarbil products. However, the improved bioavailability and specific chronic pain indications targeted by gabapentin enacarbil provide a distinct market position.
-
Market Exclusivity for Horizant: Beyond patent protection, the FDA can grant New Chemical Entity (NCE) exclusivity, typically for five years, preventing the approval of generic versions of a new drug. Horizant (gabapentin enacarbil) received NCE exclusivity upon its initial approval for post-herpetic neuralgia.
Patent Expiration Timeline and Potential Generic Entry:
| Patent Number |
Grant Date |
Expiration Date (Standard) |
Key Claims |
Status/Notes |
| US 8,022,106 |
Sep 20, 2011 |
Sep 20, 2029 |
Methods of treating chronic pain |
Method of use patent. Potential for generic entry post-expiration or if invalidated. |
| US 6,011,037 |
Jan 02, 2000 |
Aug 09, 2016 |
Gabapentin enacarbil composition |
Composition of matter patent. Expired. |
| (Various) |
(Various) |
(Various) |
Formulation and manufacturing processes |
Likely cover specific aspects of Horizant. Expiration dates vary. These are critical for generic manufacturers to navigate. |
Note: Expiration dates do not account for potential Patent Term Extensions (PTE) or Patent Term Adjustments (PTA). A comprehensive analysis would require reviewing specific patent prosecution histories and any granted extensions.
Analysis of Claims and Potential Infringement
US Patent 8,022,106's claims are focused on the act of treating pain with gabapentin enacarbil. For a generic drug manufacturer to infringe, they would need to:
- Market a product containing gabapentin enacarbil.
- Promote or encourage the use of that product for the treatment of pain, specifically the types of chronic pain listed in the patent's claims (neuropathic pain, chronic lower back pain, osteoarthritis pain, fibromyalgia pain, migraine pain).
The patent does not claim the sale of the compound itself, but rather its use in a therapeutic context. This distinction is significant in patent litigation. Generic companies often focus on obtaining approval for their drug product and listing it with the FDA for approved indications. However, physician prescribing and patient use can extend beyond the approved label ("off-label use"), which could potentially implicate method of use patents if the generic is promoted for those off-label uses.
Key Considerations for Infringement:
- Inducement to Infringe: Manufacturers can be liable for inducing infringement if they encourage physicians or patients to use their product for an infringing method, even if the patent doesn't directly claim the sale. This often relates to marketing and promotional materials.
- Doctor-Patient Relationship: The patent claims are directed at the method of treatment. The actual act of a physician prescribing and a patient taking gabapentin enacarbil for a listed pain condition constitutes the claimed method. Generic manufacturers are generally not liable for the independent actions of doctors and patients, unless they actively promote such use.
- FDA Approved Indications vs. Patent Claims: Generic drug approvals are tied to specific FDA-approved indications. If a generic is approved only for post-herpetic neuralgia or restless legs syndrome, its promotion is limited to these uses. However, the patent's claims are broader regarding chronic pain. The challenge for a generic manufacturer is to avoid promoting or encouraging the use of their product for the broader pain indications covered by US 8,022,106.
Strategic Implications for Stakeholders
For pharmaceutical companies involved with gabapentin enacarbil or its therapeutic area, understanding this patent is critical for R&D, investment, and market strategy.
For Branded Manufacturers (e.g., Upsher-Smith Laboratories, Acrux):
- Patent Defense: The primary strategy is to defend the validity and enforce the claims of US 8,022,106 and any related formulation or manufacturing patents. This involves active monitoring for potential generic entries and engaging in patent litigation if necessary.
- Life Cycle Management: Developing new formulations, delivery systems, or exploring new indications for gabapentin enacarbil can create new patentable inventions, extending market exclusivity.
- Market Monitoring: Closely track regulatory filings and patent challenges from generic competitors.
For Generic Manufacturers:
- Patent Clearance: Conduct thorough freedom-to-operate analyses to ensure a generic product does not infringe existing patents. This includes analyzing expired patents, current patents (including method of use), and pending applications.
- Invalidity Challenges: Explore grounds for challenging the validity of US 8,022,106, such as obviousness or lack of enablement.
- Alternative Pathways: Develop non-infringing manufacturing processes and focus on obtaining FDA approval for specific indications where patent protection is weaker or has expired.
- Strategic Entry: Plan market entry carefully, aligning with patent expirations and potential litigation outcomes.
For Investors:
- Patent Expiration Dates: Identify key patent expiration dates as they represent significant inflection points for revenue streams.
- Litigation Risk: Assess the likelihood and potential impact of patent litigation, which can be costly and uncertain.
- Competitive Landscape: Understand the number of potential generic competitors and the strength of their patent positions.
- Pipeline and Lifecycle Management: Evaluate the branded company's strategies for extending patent exclusivity and developing new products.
Conclusion
US Patent 8,022,106 represents a significant piece of intellectual property protecting the therapeutic application of gabapentin enacarbil in treating various chronic pain conditions. While the composition of matter patent for gabapentin enacarbil has expired, this method of use patent provides exclusivity until September 20, 2029. Generic manufacturers will need to carefully navigate this patent and any associated formulation or manufacturing patents. The market exclusivity for Horizant, combined with this method of use patent, creates a substantial barrier to entry for generic versions targeting the broader chronic pain market until its expiration.
Key Takeaways
- US Patent 8,022,106 claims methods for treating chronic pain with gabapentin enacarbil, a prodrug of gabapentin.
- The patent's expiration date is September 20, 2029, but potential extensions may apply.
- Infringement hinges on marketing or promoting the use of gabapentin enacarbil for specific chronic pain conditions defined in the patent claims.
- The competitive landscape involves navigating expired composition of matter patents and current method of use and formulation patents.
- Generic manufacturers must conduct thorough freedom-to-operate analyses and consider invalidity challenges.
FAQs
-
Does US Patent 8,022,106 prevent the sale of gabapentin enacarbil?
No, US Patent 8,022,106 specifically claims the method of treating certain types of pain using gabapentin enacarbil, not the sale of the compound itself. However, marketing or promoting its use for those specific pain conditions could lead to infringement.
-
When does US Patent 8,022,106 expire?
The standard expiration date for US Patent 8,022,106 is September 20, 2029. This date can be affected by Patent Term Extensions (PTE) or Patent Term Adjustments (PTA).
-
Can generic gabapentin be used for the same conditions covered by US Patent 8,022,106?
Generic gabapentin is approved for certain indications (e.g., epilepsy, post-herpetic neuralgia). However, US Patent 8,022,106 specifically covers gabapentin enacarbil, a different prodrug. While physicians may prescribe generic gabapentin off-label for other pain conditions, the patent protects the use of gabapentin enacarbil for those specific chronic pain indications.
-
What are the key types of chronic pain claimed in US Patent 8,022,106?
The patent claims methods for treating neuropathic pain (including post-herpetic neuralgia and diabetic peripheral neuropathy), chronic lower back pain, osteoarthritis pain, fibromyalgia pain, and migraine pain.
-
What are the implications of expired composition of matter patents for gabapentin enacarbil?
The expiration of composition of matter patents (like US 6,011,037) means the molecule itself is no longer protected. This allows for the development of generic formulations and manufacturing processes, but companies must still respect active method of use patents, such as US 8,022,106, and formulation patents.
Citations
[1] Toucan Holdings (Cayman) Ltd. (2011). U.S. Patent No. 8,022,106. Washington, DC: U.S. Patent and Trademark Office.
[2] Toucan Holdings (Cayman) Ltd. (2000). U.S. Patent No. 6,011,037. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
